Alta Sciences

JULY 5, 2023

How to Facilitate Your Ophthalmic Drug Development tchichekian Thu, 07/06/2023 - 01:11 HTML From Discovery to Market, We’ve Got You Covered. As a leading partner in ophthalmic drug development , Altasciences has an outstanding track record formulating, testing, and manufacturing ophthalmic products.

Drug Development 52

Drug Development Drugs Clinical Research Production 52

Conversations in Drug Development Trends

OCTOBER 24, 2023

While this is a small number of people in each rare disease patient community, the significant and continued growth of rare disease drug development is unsurprising given that there are over 10,000 rare diseases , with more being discovered every year.

Clinical Trials 52

Clinical Trials Disease Therapies Drug Development 52

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

PPD

FEBRUARY 22, 2023

These anecdotal struggles were highlighted in industry research conducted by PPD, the clinical research business of Thermo Fisher Scientific. In a survey of more than 150 global drug development leaders, more than a quarter (28%) cited lack of R&D funding as the top challenge facing their organization.

Clinical Research 52

Clinical Research Biosimilars Marketing Trials 52

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

LifeSciVC

JULY 11, 2023

The meeting brings together tens of thousands of physicians, scientists, patients, advocates, innovators, and those involved in oncology drug development from around the world in order to explore the latest advances in cancer treatment, clinical trials, and translational and clinical research.

Therapies 67

Therapies Trials Clinical Development Science 67

PPD

NOVEMBER 30, 2023

As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the Drug Development Industry in 2024 1.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

Conversations in Drug Development Trends

NOVEMBER 10, 2023

If you’re interested in learning more about pain therapeutics research, check out our pain expertise. The post 3 Considerations of the Patient Perspective from the 2023 Pain Therapeutics Summit appeared first on Worldwide Clinical Trials.

Clinical Trials 75

Clinical Trials Trials Compliance Treatment 75

Conversations in Drug Development Trends

JANUARY 24, 2024

However, clinical research around Fragile X is considerably robust, making the possibility of clinical trial participation a potential motivation for parents to choose to undergo genetic testing for their children. As of July 2023, the American Society of Cell + Gene Therapy stated there were 3,905 therapies in development.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Vial

MARCH 1, 2024

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). By geographical region, the global CRO services market in 2023 was dominated by North America. billion in 2023 attributable to its laboratory products and biopharma services segment (53.8%

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

PPD

JUNE 27, 2024

Our expertise in alopecia areata studies As of July 2023, there were more than 60 planned or ongoing clinical trials for alopecia areata, involving nearly 20 pharmaceutical or biotech organizations. CorEvitas will be deploying AA focus groups among physicians and patients to provide insights for pragmatic clinical trial designs.

Treatment 52

Treatment Clinical Trials Clinical Research Small Molecule 52

Conversations in Drug Development Trends

DECEMBER 7, 2023

However, despite their greater service capabilities, large CROs have hit an inflection point in the clinical landscape, leading to unexpected industry dynamics characterized by a rise in CROs that take a more personalized approach.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

PPD

JUNE 22, 2023

If your company is struggling to hire qualified clinical research associates (CRAs), you’re not alone. A decade-long CRA talent shortage intensified as the COVID-19 pandemic increased strain on the clinical research industry at large. Climbing demand is driving the CRA talent gap.

Clinical Research 52

Clinical Research Clinical Trials Trials Drug Development 52

Agency IQ

OCTOBER 27, 2023

What We Expect the FDA to do in November 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

Vial

FEBRUARY 29, 2024

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. between 2023 and 2032. By 2032, this value is expected to reach US$108 billion.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

PPD

NOVEMBER 21, 2023

The drug development industry is constantly adapting and evolving to bring novel therapeutics to market to improve the lives of patients across the globe. While the drug development industry experienced setbacks during the COVID-19 pandemic, the field  is again gaining momentum reminiscent of its pre-pandemic pace.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

What will have the greatest impact on rare disease patients in 2023? Katie Nichols, senior project manager at Worldwide Clinical Trials, has been dedicated to rare disease research for seven years, seeing the impact firsthand that the progression of rare disease research has on rare disease communities.

Disease 52

Disease Clinical Trials Trials Treatment 52

Alta Sciences

AUGUST 28, 2023

Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI) pmjackson Mon, 08/28/2023 - 14:04 Laval, Québec, August 30, 2023 – Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s is a privately held drug development company based in Grafton, MA.

Trials 40

Trials Treatment Clinical Pharmacology Pharmacokinetics 40

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. The company reported a revenue of $11,116 million for the first nine months of 2023, marking a 4.2%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

Vial

DECEMBER 5, 2023

Next-generation sequencing (NGS) has revolutionized scientific research and clinical genomics due to high-throughput multiplexing and shed light on genome structure, function, and dynamics. It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

Alta Sciences

DECEMBER 14, 2023

A Closer Look At Our On-Site Compounding Pharmacies shajjar Thu, 12/14/2023 - 21:30 HTML Altasciences' dedicated pharmacists bring a wealth of expertise in controlled substances and complex compounding, ensuring maximum precision and safety standards. Electronic security access to the pharmacy and video monitoring. -

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

PPD

NOVEMBER 14, 2023

Clinical research requires vast talent across a variety of roles and specialties, as well as across global locations. In this complex environment, functional service partnership (FSP) models have become a solution of choice for pharmaceutical and biotech companies navigating the challenges of clinical development.

Clinical Research 52

Clinical Research Clinical Development International Engineering 52

PPD

OCTOBER 31, 2023

If recruitment moves slowly or individuals with the wrong skills are selected, the clinical research process stalls, costing sponsors valuable time, money and resources. Selecting the Right Partnership Model Clinical research outsourcing models have changed over time to accommodate the industry’s evolving needs.

International 52

International Clinical Research Clinical Development Research 52

Vial

DECEMBER 13, 2023

In 2023, more than half of the sponsors surveyed (65%) were concerned if sites viewed them as a sponsor of choice, up from only 14% in 2019. A site satisfaction survey conducted by Greenphire revealed that sites and sponsors both seek opportunities to improve clinical trial processes.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

PPD

NOVEMBER 7, 2023

The underrepresentation of diverse groups in clinical research is an area of regulatory, scientific and industry focus, partly due to the recent U.S. Food and Drug Administration (FDA) draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.”

Clinical Trials 59

Clinical Trials Trials Clinical Research Disease 59

Alta Sciences

SEPTEMBER 13, 2023

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials pmjackson Wed, 09/13/2023 - 17:01 September is pain awareness month, and the importance of pain management and continued research into effective analgesics is integral to helping patients suffering from various pain conditions.

Clinical Trials 52

Clinical Trials Treatment Trials Drug Development 52

Vial

APRIL 18, 2024

The urgency for novel therapeutic approaches makes ophthalmology a rapidly growing domain of clinical research. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

PPD

JULY 13, 2023

Their services help engage a suitable participant pool, facilitate clinical trial participation, ensure that selected sites have the resources to support clinical trial activities and more. Patient education programs and resources can help inform potential participants of the critical role they can play in clinical research.

Pharma Companies 52

Pharma Companies Clinical Trials Trials Clinical Research 52

PPD

JUNE 20, 2023

As some drug development organizations right-size their workforces , a strong CRO partner will rehire your talent — avoiding destabilization of your clinical research — via rebadging through functional service provider (FSP) engagements. The drug development industry is undoubtedly in a season of change.

Clinical Trials 52

Clinical Trials Drug Development Trials Clinical Research 52

Vial

FEBRUARY 15, 2024

Sponsors often contract a CRO to delegate specific day-to-day tasks, streamlining their research processes and enhancing efficiency. Conclusion As the global clinical trials outsourcing market continues to expand, CROs are increasingly recognized as essential partners in the drug development ecosystem.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

PPD

MARCH 28, 2024

The biotech index (XBI) has already shown promising signs as well, having bottomed out mid-2023 and steadily building a base since then. This trend indicates that market participants view many public companies as attractive bargains, boosting the availability of follow-on offerings and PIPEs for additional funding opportunities.

Trials 52

Trials Clinical Trials Drug Development Clinical Research 52

Drug Target Review

OCTOBER 25, 2024

2023, September 9). 2023, July 24). The Role of Biomarkers in Alzheimer’s Disease Drug Development. Postmortem Brain Imaging in Alzheimer’s Disease and Related Dementias: The South Texas Alzheimer’s Disease Research Center Repository. References Juganavar, A., Joshi, A., & Shegekar, T.

Disease 59

Disease Clinical Trials Therapies Science 59

Vial

FEBRUARY 26, 2024

The pharmaceutical and biotechnological landscape is constantly evolving and a key partner within the drug development process is contract research organizations (CROs) , who are at the forefront with sponsors to drive innovation in clinical research.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceuticals 52

PPD

JUNE 17, 2024

One interesting trend emerging from the 2023 Pulse Report is the rise of hybrid functional service provider (FSP)/full-service outsourcing (FSO) arrangements. Partner with an FSP provider that delivers results across every use case Drug developers count on strategic collaborations for success, and those collaborations come in many forms.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

Conversations in Drug Development Trends

NOVEMBER 27, 2023

In June 2023, the U.S. Food and Drug Administration (FDA) announced its acceptance of the Biologics License Application (BLA) for exa-cel. In recognition of the unmet need and medical urgency for innovative therapies in the sickle cell space, the FDA granted exa-cel Priority Review, with a formal decision expected by December 8, 2023.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

Drug Target Review

SEPTEMBER 26, 2023

CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact.

Drugs 111

Drugs FDA Disease Animal Testing 111